This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
The company has posted net profit of Rs. 283 crore for the 6 months period ended September 30, 2025
Tatva Chintan Pharma Chem has reported total income of Rs. 124.52 crore during the period ended September 30, 2025
With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
